Enrolment | Treatment period | Follow-up | |||||||
---|---|---|---|---|---|---|---|---|---|
Screening/Consent | Visit 1 (baseline and first day of treatment) | Visit 2 (after 24 ± 4 h on amantadine) | Visit 3 (after 48 ± 4 h on amantadine) | Visit 4 (after 72 ± 4 h on amantadine) | Visit 5 (after 96 ± 4 h on amantadine) | Visit 6 (after 120 ± 4 h on amantadine) | Visit 7 (14 days after last dose) | Visit 8* (after 3 months ± 7 days from1st dose) | |
Timeline (days) | 1 | 2 | 3 | 4 | 5 | 6 | - | 90 | |
Informed consent | X | ||||||||
Inclusion /exclusion criteria | X (using a screening sheet) | X (recheck) | |||||||
Patient history, demographics | X | ||||||||
Documentation of clinical data | X | ||||||||
Documentation of drug history | X | ||||||||
Physical and Neurological examination | X | ||||||||
Blood tests (approx. 10 ml) | X | ||||||||
Start of trial drug | X | ||||||||
Responsiveness check | X* | ||||||||
Pregnancy Test (measurement of hCG in serum) in woman of child bearing potential | X | ||||||||
GCS | X* | X | X* | X | X | X* | X | X | |
FOUR Score Coma Scale | X | X | X | X | X | X | X | X | |
RASS | X | X | X | X | X | X | X | X | |
ICDSC | X | X | X | X | X | X | X | X | |
EEG | X | X | X | ||||||
ECG | X | X | X | X | X | X | X | ||
mRS | X | X | X | ||||||
NIHSS | X | X | X | ||||||
GOS-E | X | X | X | X | X | X | X | X | |
CRS-R | X | X | X | X | X | X | X | X | |
MoCA | X | X | |||||||
Questionnaire for therapists | X | X | X | X | X | X | X | (X) | |
Documentation of (S)AE | X | X | X | X | X | X | X |